CAR-T cell therapy has demonstrated remarkable success in treating hematologic malignancies and is now expanding into solid tumors. On June 1, 2025, The Lancet published positive results from the world’s first randomized controlled trial of CLDN18.2 specific CAR-T in gastric cancer, led by Professor Lin Shen’s team at Peking University.
British antibody specialist Alchemab Therapeutics Ltd has secured a US$32m Series A extension after it completing preclinical development of ATLX-1282 and starting a Phase I clinical trial.
In a US$450m deal with UK-based Kaerus Bioscience Ltd, Servier SA has acquired the development and commercialisation rights to KER-0193, a Phase II-ready drug candidate for the treatment of rare Fragile X syndrome, the most common monogenic cause of autism.
British mitochondrial dysfunction specialist NRG Therapeutics Ltd. (“NRG”) has closed an oversubscribed £50m Series B financing. Funds will be used to to achieve clinical proof of concept for NRG5051 in amyotrophic lateral sclerosis (ALS)/motor neurone disease (MND) and to generate Phase Ib data in Parkinson’s disease.
The Eppendorf BioFlo 120 bioprocess controller offers simplicity and ease of use, without sacrificing capability. No matter if you are in an academic, governmental or industrial research setting, the BioFlo 120 bioprocess controller is an attractive solution to meet your needs – all at an affordable price.
Data on the primary endpoint of BioNTech’s/Duality Biologics’ pivotal Phase III study of its HER2 antibody-drug conjugate BNT323/DB-1303 are not yet public, However, BioNTech says that progression-free survival is better than with Roche’s second-line breast cancer therapy Kadcyla.
Experts from the six science academies united in EASAC have called for the immediate establishment of a transparent framework across the EU for the production of biotechnologically manufactured meat alternatives.
Belgian VIB spin-out MRM Health NV is using fresh funds raised in a €55m follow-on financing round to make its microbiome preparation MH002 licensable in an ongoing Phase IIb study for the indication ulcerative colitis. With €55m (US$64m) in Series B financing,
Swiss pharma major Novartis AG is investing money in the inhibition of the Parkinson’s target alpha-synuclein, which has already failed several times in clinical trials. The Swiss company is licensing the siRNA programme ARO-SNCA from Arrowhead Pharmaceuticals for US$200m.
California-based Cytokinetics Inc (CYTK) recorded a big jump in Nasdaq prices, at 40.45%, after presenting the results of its Phase III MAPLE-HCM study at the European Society of Cardiology Congress 2025.
Alchemab Therapeutics Ltd
FRAXA Ewsearch Organisation
adobe stock photos - deemerwha
Eppendorf
Marcus Krauss - stock.adobe.com 
adobe stock photo - Blackmint Studio
adobe stock photos - nobeastsofierce 
Marvin 101 - wikipedia.org
By Coolcaesar - wikipedia.org